 | | Vol. 11.42 – 27 October, 2022 |
| |
|
|
| Scientists generated recombinant SARS–CoV-2 harbouring a catalytically inactive 2′-O-methyltransferase Nsp16, Nsp16mut, and analyzed viral replication in human lung epithelial cells.
[EMBO Reports] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers studied the interactions between JAK1/STAT3 signaling and TGF-β induced fibroblast responses using both pharmacological and small interfering RNA approaches in human normal and idiopathic pulmonary fibrosis-derived lung fibroblasts.
[American Journal of Physiology-Lung Cellular and Molecular Physiology] |
|
|
|
| Scientists identified that FOXF1 Adjacent Non-Coding Developmental Regulatory RNA (FENDRR) was downregulated in hypoxic pulmonary artery endothelial cells (HPAECs), and involved in hypoxia-induced pyroptosis of HPAECs.
[Molecular Medicine] |
|
|
|
| Investigators found that high expression of the alternatively activated tumor-associated macrophage marker, CD206+ was associated clinically with a poorer prognosis and metastasis state in patients with small cell lung cancer.
[Cell Death & Disease] |
|
|
|
| Researchers presented that H3.3, encoded by two genes, H3F3A and H3F3B, were prominently overexpressed in SCLC, and Darinaparsin, a derivative of arsenic trioxide, dose- and time-dependently inhibited the viability of SCLC cells in an H3.3-dependent manner.
[Acta Pharmacologica Sinica] |
|
|
|
| Scientists clarified the initial survival mechanisms of tumor cells in NSCLC during treatment with lorlatinib, a ROS proto-oncogene 1 (ROS1) tyrosine kinase inhibitor.
[Cancer Science] |
|
|
|
| Potential impacts of LncRNA surfactant associated 1 on lung adenocarcinoma (LUAD) were determined through the Cancer Genome Atlas database and Gene Expression Profiling Interactive Analysis. The metastatic ability of LUAD cells was also evaluated by molecular biology experiments.
[International Journal of Pharmaceutics] |
|
|
|
|
| Investigators describe the major mechanisms of damage, regeneration, and repair within the alveolar niche where gas exchange occurs.
[Annual Review of Pathology-Mechanisms of Disease] |
|
|
|
| The authors summarize the latest progress in the biological function of m6A modifications in lung diseases and discuss the potential therapeutic and prognostic strategies.
[Experimental Biology and Medicine] |
|
|
|
|
| G1 Therapeutics, Inc. announced that it is supporting a Phase II investigator-initiated study of trilaciclib and lurbinectedin in patients with extensive stage NSCLC.
[G1 Therapeutics, Inc.] |
|
|
|
| HpVac SA announced new data on its lead compound HpVac-13 for the treatment and prevention of asthmatic attacks in an animal disease model of allergic asthma.
[HpVac SA (GlobeNewswire)] |
|
|
|
|
| April 23 – 28, 2023
Cancun, Mexico |
|
|
|
|
|
| | University of Antwerp – Antwerp, Belgium |
|
|
|
| | University of Miami – Miami, Florida, United States |
|
|
|
| | AstraZeneca – Gaithersburg, Maryland, United States |
|
|
|
| | University of Cincinnati – Cincinnati, Ohio, United States |
|
|
|
| | NCI – Bethesda, Maryland, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
